Status:
COMPLETED
Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL
Lead Sponsor:
Aarhus University Hospital
Collaborating Sponsors:
Uppsala University
University of Aarhus
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Up to 45 years
Brief Summary
Asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL). Clinical hypersensitivity reactions and PEG-asparaginase inactivation is common (12-13% of the patients on the NOP...
Detailed Description
In comparison to the previous NOPHO ALL2008 protocol, the current A2G protocol aims at reducing the treatment intensity for patients with a good prognosis. More than 50% of the patients do no longer r...
Eligibility Criteria
Inclusion
- Treated for acute lymphoblastic leukemia (ALL) on the ALLTOGETHER main protocol
Exclusion
- None
Key Trial Info
Start Date :
July 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2023
Estimated Enrollment :
649 Patients enrolled
Trial Details
Trial ID
NCT06195735
Start Date
July 17 2020
End Date
December 21 2023
Last Update
January 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus N, Denmark, 8200